Advertisement vbandhakavi, Author at Pharmaceutical Business review - Page 3 of 172
Pharmaceutical Business review is using cookies

ContinueLearn More

All articles by vbandhakavi 

Ardelyx resubmits NDA for Xphozah to US FDA

A first-in-class, phosphate absorption inhibitor, Xphozah will be used to control serum phosphate in adults with chronic kidney disease (CKD) on dialysis and who had an insufficient response

Abliva’s NV354 receives ODD from US FDA

Sweden-based Abliva has announced that its drug candidate NV354 has been received orphan drug designation (ODD) from the US FDA Office of Orphan Products Development to treat mitochondrial